IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. (IDXX) Market Cap

IDEXX Laboratories, Inc. has a market capitalization of $46.05B.

Financials based on reported quarter end 2025-12-31

Price: $578.35

β–² 9.34 (1.64%)

Market Cap: 46.05B

NASDAQ Β· time unavailable

CEO: Jonathan J. Mazelsky

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1991-06-21

Website: https://www.idexx.com

IDEXX Laboratories, Inc. (IDXX) - Company Information

Market Cap: 46.05B Β· Sector: Healthcare

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Analyst Sentiment

68%
Buy

Based on 22 ratings

Analyst 1Y Forecast: $767.00

Average target (based on 4 sources)

Consensus Price Target

Low

$730

Median

$793

High

$830

Average

$784

Potential Upside: 35.6%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ IDEXX Laboratories, Inc. (IDXX) β€” Investment Overview

🧩 Business Model Overview

IDEXX Laboratories, Inc. operates as a global leader in veterinary diagnostics, veterinary practice management software, and water microbiology testing. Its primary focus is on companion animal healthcare, providing advanced diagnostic and information technology-based products and services for veterinary practices worldwide. The company's core offerings include point-of-care diagnostics, laboratory services, and digital imaging solutions, all designed to improve clinical decision-making and patient care. IDEXX’s customer base consists largely of veterinary professionals, ranging from individual clinics and animal hospitals to large healthcare networks and specialty laboratories. The company also provides diagnostic solutions for livestock and poultry health as well as testing for the water and dairy industries, though its primary revenue is driven by the animal healthcare segment.

πŸ’° Revenue Model & Ecosystem

IDEXX generates revenue through a diversified model comprising consumables, diagnostic hardware, subscription-based software solutions, laboratory services, and ongoing customer support. The sale and recurring use of diagnostic instruments are closely tied to revenues from proprietary reagents and consumables, which creates an annuity-like revenue stream as customers regularly require replenishments. In addition, IDEXX offers integrated veterinary practice management software delivered via subscription models, fostering deeper relationships with enterprise and small business customers alike. Service contracts and technical support also represent important recurring revenue channels. This interconnected ecosystem of hardware, consumables, software, and laboratory services is designed to promote customer retention and seamless workflow integration.

🧠 Competitive Advantages

  • Brand strength: IDEXX is widely recognized as a leading innovator and gold standard provider in veterinary diagnostics, known for quality, reliability, and technological leadership.
  • Switching costs: Deep integration of hardware, software, and laboratory workflows increases the complexity and cost for customers to switch to competing solutions.
  • Ecosystem stickiness: The subscription-based services, consumables tie-in, and training/support infrastructure create a high degree of customer dependency and recurring engagement.
  • Scale + supply chain leverage: Global reach, economies of scale, and an established supply chain enable IDEXX to innovate rapidly and deliver consistent service, strengthening its competitive moat against smaller or less integrated firms.

πŸš€ Growth Drivers Ahead

IDEXX stands to benefit from several durable, multi-year growth trends. Rising levels of pet ownership globally, combined with increasing willingness to spend on companion animal health, underpin growing demand for diagnostic testing and preventative care. Advances in veterinary medicine and a greater focus on early disease detection are expanding the addressable market for advanced diagnostics. IDEXX is continually expanding its menu of diagnostic tests, developing next-generation analyzers, and driving digital transformation through its software offerings. Geographic expansion, particularly in underpenetrated international markets, and the broadening of its companion animal customer base present further opportunities. Additionally, cross-selling opportunities between consumables, services, and software bolster long-term growth potential.

⚠ Risk Factors to Monitor

Key risks for IDEXX include intensifying competition from both established players and new entrants in the veterinary diagnostics space, which could pressure pricing or margins. Regulatory changes affecting animal health, diagnostic approvals, or data privacy could create operational headwinds. As diagnostic technology evolves, ongoing innovation is required to fend off potential disruption. Margin pressures may also arise from increased R&D investments, labor costs, or shifts in product/service mix. Lastly, macroeconomic downturns or shifts in pet ownership patterns could moderate demand for companion animal care.

πŸ“Š Valuation Perspective

The market typically values IDEXX at a premium compared to other life sciences and diagnostics peers, reflecting its dominant position, recurring revenue mix, and long-term growth profile. This valuation stance embodies investor confidence in the company’s ability to deliver sustained, above-industry-average growth and consistently high returns on invested capital, supported by its established competitive moat and resilience across economic cycles.

πŸ” Investment Takeaway

IDEXX Laboratories offers a compelling long-term investment profile underpinned by strong brand equity, high barriers to entry, and exposure to attractive secular trends in pet healthcare. The company’s integrated ecosystem and recurring revenue streams provide operational resilience and growth visibility. However, its premium valuation, reliance on ongoing innovation, and exposure to competitive and regulatory risks merit careful consideration. Investors should weigh the strength and durability of IDEXX’s competitive position against the potential for disruption or external shocks in an evolving pet and diagnostics landscape.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"IDXX delivered strong earnings growth in the latest quarter (2025-12-31). Revenue rose to $1.09B, up 1.40% QoQ (from $1.11B) and up 14.38% YoY (vs. $954.3M). Net income increased to $248.2M, down 9.62% QoQ (from $274.6M) but up 14.91% YoY (vs. $216.1M). EPS followed the same pattern, rising YoY to $3.10 (+17.7%) while easing QoQ to $3.10 (-9.6%). Profitability shows mixed timing but an overall positive YoY picture: net margin was ~22.8% (248.2/1,090.6), down slightly QoQ (~24.8%) yet up YoY (~22.6% vs. 22.7%β€”roughly stable to modestly improved). Over the broader 4-quarter window, EPS and net income were highest around 2025-06-30 to 2025-12-31, indicating resilient profitability despite quarterly variability. Balance sheet strength appears solid for a mature healthcare/diagnostics business: total assets were $3.35B, with equity at $1.61B. Equity dipped from earlier in 2025 but remains stable versus year-end 2024. With no dividends, β€œshareholder return” is primarily capital appreciation: the stock gained 46.44% over 1 year (>20% momentum), which meaningfully boosts the total-return view. Analyst valuation context: consensus target (~$784) vs. current price ($589.25) implies upside of ~33%."

Revenue Growth

Strong

Latest revenue of ~$1.09B was +14.38% YoY, but -1.40% QoQ versus the prior quarter ($1.11B). Growth is clearly positive year-over-year despite some sequential softness.

Profitability

Good

Net income margin was ~22.8% in the latest quarter, down vs. QoQ (~24.8%) but broadly stable vs. the prior-year period. EPS was +17.7% YoY, indicating underlying earnings momentum.

Cash Flow Quality

Positive

Cash flow metrics (operating cash flow/free cash flow) were not provided; using net income as a proxy, profitability is solid and rising YoY. No dividends and no explicit buyback data in the dataset limit confidence on cash-return durability.

Leverage & Balance Sheet

Good

Total assets increased to ~$3.35B. Equity is ~$1.61B. Net debt was higher in 2025 versus 2024 (worsened from ~$699M to ~$897M), but remains manageable for a profitable business.

Shareholder Returns

Excellent

With no dividend, total shareholder return is dominated by price appreciation. The stock’s 1-year gain of +46.44% (well above +20% momentum) is a strong positive signal.

Analyst Sentiment & Valuation

Strong

Consensus target of ~$784.38 vs. current ~$589.25 implies ~33% upside, supporting constructive valuation sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

IDEXX delivered a strong Q4 and FY25, with double-digit organic growth, record instrument placements, margin expansion, and EPS outperformance. Despite persistent pressure on US clinical visits, the company is benefiting from increased diagnostic frequency, a growing installed base, and strong international demand. FY26 guidance calls for 7%–9% organic growth, margin expansion, and double-digit EPS growth, with FX a modest tailwind and instrument revenues expected to decline as the company laps the InVue Dx launch. Overall tone was confident, highlighting durable recurring revenues, robust innovation, and enhanced commercial execution, while acknowledging sector and macro headwinds.

Growth

  • Q4 revenue +14% reported, +12% organic
  • Q4 CAG +13% organic; Water +10% organic; LPD +4% organic
  • Q4 CAG Diagnostics recurring revenue +10% organic (US +9%; International +12%)
  • Q4 VetLab consumables +15% organic; CAG diagnostic instrument revenue +69% organic
  • Q4 Rapid Assay -3% organic (pancreatic lipase shift to Catalyst slide ~4% headwind)
  • Q4 Reference Lab +9% organic; Imaging +13% organic (cloud PIMS recurring double-digit growth)
  • FY25 organic revenue +10%; FY25 CAG Diagnostics recurring +8%
  • Q4 revenue growth premium vs US clinical visits ~1,100 bps (US same-store visits -1.7% in Q4)

Business Development

  • Record premium instrument placements in Q4 (6,567; +42% y/y) across major platforms
  • Over 1,900 InVue Dx placements in Q4; ~6,400 units in FY25; >$75M instrument revenue contribution (~200 bps to company growth)
  • Premium instrument installed base +12% y/y; ~22,500 placements in FY25; nearly 78,000 Catalyst analyzers globally
  • CancerDx adoption reached nearly 6,000 customers in North America; panel expansion to include canine mast cell tumor detection expected mid-2026
  • Cloud-based PIMS and vertical SaaS momentum with double-digit recurring revenue growth

Financials

  • Q4 gross margin 60.3% (+60 bps comparable; ~10 bps FX headwind); operating profit +17% comparable
  • Q4 operating expenses +10% comparable (R&D and commercial investments)
  • Q4 EPS $3.08 (+17% comparable); includes ~$0.07 tax benefit from SBC and ~$0.09 FX tailwind
  • FY25 operating margin 31.6% (+90 bps comparable; comps affected by lapping prior-year litigation expense)
  • FY25 EPS $13.08 (+14% comparable); includes ~$0.64 benefit from litigation accrual adjustment, ~$0.10 FX, ~$0.35 tax benefit from SBC
  • FX impact FY25: ~80 bps revenue growth benefit; +$10M operating profit; -$1M hedge losses
  • Q1’26 outlook: reported revenue +11.5% to +13.5% (FX ~+2.5%); organic +9% to +11%; CAG recurring +8.5% to +10.5%; operating margin 31.4% to 31.9%
  • FY26 guidance: revenue $4.632B–$4.72B (+7.6% to +9.6% reported; +7% to +9% organic); CAG recurring +8% to +10% organic
  • FY26 operating margin 32.0%–32.5% reported (30–80 bps comparable expansion; ~30 bps FX benefit; ~20 bps headwind from lapping litigation accrual)
  • FY26 EPS $14.29–$14.80 (+10% to +14% comparable); includes ~$34M net interest expense and ~$0.22 FX benefit

Capital & Funding

  • FY25 free cash flow $1.1B (~100% of net income); capex $125M (~3% of revenue)
  • Repurchased 2.4M shares for $1.2B (avg $500.06); diluted shares down 2.7% y/y
  • Year-end leverage: ~0.5x gross, ~0.4x net
  • FY26 outlook: FCF conversion 85%–95% of net income; capex ~$180M (~4% of revenue); share repurchases to reduce diluted shares by 1%–2%

Operations & Strategy

  • Completed targeted commercial expansion in Germany, UK, Australia, and US; reduced accounts per rep to increase engagement
  • High customer retention in global CAG Diagnostics (high-90s)
  • Focus on increasing diagnostics frequency and utilization per visit; productivity initiatives in labs and operations
  • Supply continuity plans in place; tariffs under current laws included in outlook
  • Expansion of high-margin cloud-based software business

Market & Outlook

  • US same-store clinical visits remain pressured (-1.7% Q4; -1.9% FY25); wellness visits -3.6% in Q4
  • Aging pet population supporting demand; improving visits in canines 5+ years; higher diagnostics per visit
  • FY26 assumptions: global net price realization ~4% (US ~3.5%); US same-store visits ~-2%
  • International demand remains strong; continued double-digit growth in international installed base
  • FX expected to benefit FY26 revenue growth by ~60 bps (largely 1H) and EPS by ~$0.22; sensitivity: 1% USD move β‰ˆ $16M revenue and $5M operating income

Risks Or Headwinds

  • Sustained pressure on US clinical visits, especially wellness/discretionary
  • Expected decline in CAG instrument revenues in FY26 as the company laps rapid InVue Dx rollout and faces regional mix dynamics
  • Rapid Assay headwinds from test menu migration (e.g., pancreatic lipase to Catalyst)
  • FX volatility despite hedging; tariff exposure (captured in outlook)
  • Gross margin mix pressure when instrument revenue is elevated
  • Macro and sector constraints could weigh on visit trends and discretionary spending

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the IDXX Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (IDXX)

Β© 2026 Stock Market Info β€” IDEXX Laboratories, Inc. (IDXX) Financial Profile